- Home
- PRT vs BDSX Comparison
PRT vs BDSX Comparison
Compare PRT & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRT
- BDSX
- Stock Information
- Founded
- PRT 2017
- BDSX 2005
- Country
- PRT United States
- BDSX United States
- Employees
- PRT N/A
- BDSX N/A
- Industry
- PRT Oil & Gas Production
- BDSX Precision Instruments
- Sector
- PRT Energy
- BDSX Health Care
- Exchange
- PRT Nasdaq
- BDSX Nasdaq
- Market Cap
- PRT 48.1M
- BDSX 61.9M
- IPO Year
- PRT N/A
- BDSX 2020
- Fundamental
- Price
- PRT $3.94
- BDSX $7.53
- Analyst Decision
- PRT
- BDSX Strong Buy
- Analyst Count
- PRT 0
- BDSX 5
- Target Price
- PRT N/A
- BDSX $32.50
- AVG Volume (30 Days)
- PRT 32.1K
- BDSX 73.0K
- Earning Date
- PRT 11-12-2025
- BDSX 10-31-2025
- Dividend Yield
- PRT 10.75%
- BDSX N/A
- EPS Growth
- PRT 1.16
- BDSX N/A
- EPS
- PRT 0.44
- BDSX N/A
- Revenue
- PRT $6,314,770.00
- BDSX $76,556,000.00
- Revenue This Year
- PRT N/A
- BDSX $18.80
- Revenue Next Year
- PRT N/A
- BDSX $27.76
- P/E Ratio
- PRT $8.81
- BDSX N/A
- Revenue Growth
- PRT 1.82
- BDSX 25.70
- 52 Week Low
- PRT $3.26
- BDSX $3.44
- 52 Week High
- PRT $4.63
- BDSX $34.40
- Technical
- Relative Strength Index (RSI)
- PRT 51.61
- BDSX 60.86
- Support Level
- PRT $3.88
- BDSX $7.25
- Resistance Level
- PRT $3.99
- BDSX $7.81
- Average True Range (ATR)
- PRT 0.07
- BDSX 0.53
- MACD
- PRT 0.00
- BDSX -0.29
- Stochastic Oscillator
- PRT 62.48
- BDSX 12.21
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.